SCHEDULE 13G/A: Maverick Capital Discloses 5.4% Stake in Wave Life Sciences Ltd.
Beneficial Ownership Report
Maverick Capital, along with its affiliates, has disclosed a 5.4% beneficial ownership stake in Wave Life Sciences Ltd., holding 8,261,242 ordinary shares as of December 31, 2024.
Summary
- Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively reported beneficial ownership of 8,261,242 ordinary shares of Wave Life Sciences Ltd.
- This ownership represents 5.4% of the Issuer's outstanding $0 par value Ordinary Shares.
- The percentage is calculated based on 152,519,770 outstanding shares, as reported in Wave Life Sciences Ltd.'s Quarterly Report on Form 10-Q filed on November 12, 2024.
- The reporting persons, including Maverick Capital, Ltd. (an investment adviser), Maverick Capital Management, LLC (its General Partner), and Lee S. Ainslie III (manager and managing partner), share both voting and dispositive power over all 8,261,242 shares.
- The shares are held for the accounts of Maverick's clients, encompassing Maverick Fund USA, Ltd., Maverick Fund II, Ltd., Maverick Long Enhanced Fund, Ltd, Maverick HP, L.P., Maverick Long Fund, Ltd., and certain separately managed accounts.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant institutional stake, which can be seen as a vote of confidence, but provides no operational or financial performance details.
Positives
- A significant institutional investor, Maverick Capital, holds a substantial stake, potentially indicating confidence in Wave Life Sciences Ltd.'s long-term prospects.
- The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control of the issuer, suggesting a passive investment intent.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing indicates a significant institutional investment in Wave Life Sciences Ltd., a common occurrence in the public markets where large funds take positions in companies. It reflects an investor's decision to allocate capital to this specific company, but does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's position, which may influence market sentiment and perception of the company's value.
- Investment Community: Offers insight into the investment strategies of Maverick Capital and its view on Wave Life Sciences Ltd.
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date Wave Life Sciences Ltd. filed its Quarterly Report on Form 10-Q, reporting 152,519,770 outstanding ordinary shares used for ownership percentage calculation. |
| 2024-12-31 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership. |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
Wave Life Sciences Ltd., Maverick Capital, SEC filing, Schedule 13G, beneficial ownership, institutional investment, ordinary shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.